Behavioral effects of urotensin-II centrally administered in mice

Psychopharmacology

Volumn 183, Issue 1, 2005, Pages 103-117

  Do Rego, Jean Claude ^a   Chatenet, David ^b   Orta, Marie Hélène ^a   Naudin, Bertrand ^a   Le Cudennec, Camille ^a   Leprince, Jérôme ^b   Scalbert, Elizabeth ^c   Vaudry, Hubert ^b   Costentin, Jean ^a  

^a UFR Medecine Pharmacie   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Behavioral effects; Central nervous system; Mouse; Urotensin II

Indexed keywords

APOMORPHINE; UROTENSIN II;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM; CLIMBING; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; FLUID INTAKE; FOOD INTAKE; FORCED SWIMMING TEST; HORMONE RELEASE; LOCOMOTION; MALE; MAZE TEST; METABOLISM; MOUSE; NOCICEPTION; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; STRESS; TASK PERFORMANCE;

AMINO ACID SEQUENCE; ANIMALS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; EATING; EXPLORATORY BEHAVIOR; INJECTIONS, INTRAVENTRICULAR; LOCOMOTION; MALE; MAZE LEARNING; MICE; MOLECULAR SEQUENCE DATA; TIME FACTORS; UROTENSINS;

EID: 26944438330     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0140-2     Document Type: Article

References (70)

1. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao ZH, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DWP, Ohlstein EH, Bergsma DJ, Douglas SA (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GRP14. Nature 401:282-286
2. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1-12
3. Barden N, Reul JM, Holsboer F (1995) Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci 18:6-11
4. Bern HA, Pearson D, Larson BA, Nishioka RS (1985) Neurohormones from fish tails: the caudal neurosecretory system. I "Urophysiology" and the caudal neurosecretory system of fishes. Recent Prog Horm Res 41:533-552
5. Blumstein LK, Crawley JN (1983) Further characterization of a simple, automated exploratory model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 18:37-40
6. Boissier JR, Simon P (1962) La réaction d'exploration chez la souris. Thérapie 17:1225-1232
7. Byrum CE, Ahearn EP, Krishnan RR (1999) A neuroanatomic model for depression. Prog Neuropsychopharmacol Biol Psychiatry 23:175-193
8. Chartrel N, Conlon JM, Collin F, Braun B, Waugh D, Vallarino M, Lahrichi SL, Rivier J, Vaudry H (1996) Urotensin II in the central nervous system of the frog Rana ridibunda: immunohistochemical localization and biochemical characterization. J Comp Neurol 364:324-339
9. Chartrel N, Leprince J, Dujardin C, Chatenet D, Tollemer H, Baroncini M, Balment RJ, Beauvillain JC, Vaudry H (2004) Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord. J Neurochem 91:110-118
10. Chatenet D, Dubessy C, Leprince J, Boularan C, Carlier L, Segala-Millazo I, Guilhaudis L, Oulyadi H, Davoust D, Scalbert E, Pfeiffer B, Renard P, Tonon MC, Lihrmann I, Pacaud P, Vaudry H (2004) Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 25:1819-1830
11. Clark SD, Northacker HP, Wang Z, Saito Y, Leslie FM, Civelli O (2001) The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat. Brain Res 923:120-127
12. Conlon JM, Tostivint H, Vaudry H (1997) Somatostatin- and urotensin II-related peptides: molecular diversity and evolutionary perspectives. Regul Pept 69:95-103
13. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA, Vaudry H (1998) Cloning of the cDNA encoding the urotensin-II precursor in frog and human reveals intense expression of the urotensin-II gene in motoneurons of the spinal cord. Proc Natl Acad Sci U S A 95:15803-15808
14. Coulouarn Y, Jegou S, Tostivint H, Vaudry H, Lihrmann I (1999) Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin-II precursors. FEBS Lett 457:28-32
15. Coulouarn Y, Fernex C, Jegou S, Henderson CE, Vaudry H, Lihrmann I (2001) Specific expression of the urotensin II gene in sacral motoneurons of developing rat spinal cord. Mech Dev 101:187-190
16. Drevets WC (1998) Functional neuroimaging studies of depression: the anatomy of melancholia. Annu Rev Med 49:341-361
17. Drevets WC, Raichle ME (1992) Neuroanatomical circuits in depression: implications for treatment mechanisms. Psychopharmacol Bull 28:261-274
18. Drevets WC, Videen TO, Price JL, Preskorn SH, Carmichael ST, Raichle ME (1992) A functional anatomical study of unipolar depression. J Neurosci 12:3628-3641
19. Drevets WC, Bogers W, Raichle ME (2002) Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 12:527-544
20. Dugovic C, Maccari C, Weibel L, Turek W, Van Reeth O (1999) High corticosterone levels in prenatally stressed rats predict persistent paradoxical sleep alterations. J Neurosci 19:8656-8664
21. Dun SL, Brailoiu GC, Yang J, Chang JK, Dun NJ (2001) Urotensin II-immunoreactivity in the brainstem and spinal cord of the rat. Neurosci Lett 305:9-12
22. Duncan GE, Knapp DJ, Breese GR (1996) Neuroanatomical characterization of Fos induction in rat behavioral methods of anxiety. Brain Res 713:79-91
23. Eddy WB, Leimbach D (1953) Synthetic (II) dithenylbutenyl and dithenylbutylamine. J Pharmacol Exp Ther 107:385-393
24. Elshourbagy NA, Douglas SA, Shabou U, Harrison S, Duddy G, Sechler JL, Ao Z, Maleeff BE, Naselsky D, Disa J, Aiyar NV (2002) Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 136:9-22
25. Eritja R, Ziehler-Martin PJ, Walker PA, Lee TD, Legesse K, Albericio F, Kaplan BE (1987) On the use of s-t-butylsulphenyl group for protection of cysteine in solid-phase peptide synthesis using fmoc-amino acids. Tetrahedron 12:2675-2680
26. File SE, Wardil AG (1975) Validity of head-dipping as a measure of exploration in a modified hole board. Psychopharmacology 44:53-59
27. Flohr S, Kurz M, Kostenis E, Brkovich A, Fournier A, Klabunde T (2002) Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance on urotensin II. J Med Chem 45:1799-1805
28. Gartlon J, Parker F, David C, Harrison DC, Douglas SA, Ashmeade TE, Riley GJ, Hugues ZA, Taylor SG, Munton RP, Hagan JJ, Hunter JA, Jones DNC (2001) Central effects of urotensin-II following ICV administration in rats. Psychopharmacology 155:426-433
29. Guelfi JD (1993) Comorbidity of anxiety-depression and its treatment. Encéphale 2:397-404
30. Haley TJ, McCormick WG (1957) Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol 12:12-15
31. Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS (1999) Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr Rev 20:68-100
32. Kinney WA, Almond HR, Qi J, Smith CE, Santulli RJ, de Garavilla L, Andrade-Gordon P, Cho DS, Everson AM, Feinstein MA, Leung PA, Maryanoff BE (2002) Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model. Angew Chem Int Ed Engl 41:2940-2944
33. Klein DF (1993) Mixed anxiety depression. For and against. Encéphale 3:493-495
34. Koster R, Andreson M, Debeer E (1959) Acetic acid for analgesic screening. Fed Proc 18:412-415
35. Labarrère P, Chatenet D, Leprince J, Marionneau C, Loirand G, Tonon MC, Dubessy C, Scalbert E, Pfeiffer B, Renard P, Calas B, Pacaud P, Vaudry H (2003) Structure-activity relationships of human urotensin II and related analogues on rat aorta ring contraction. J Enzyme Inhib Med Chem 18:77-88
36. Landgraf R, Wigger A, Holsboer F, Neumann D (1999) Hyperreactive hypothalamo-pituitary-adrenocortical axis in rats bred for high anxiety-related behavior. J Neuroendocrinol 11:405-407
37. Le Cudennec C, Naudin B, Do Rego JC, Costentin J (2002) Nociceptin/orphanin FQ and related peptides reduce the increase in plasma corticosterone elicited in mice by an intracerebroventricular injection. Life Sci 72:163-171
38. Lehmann A (1974) Atlas stéréotaxique du cerveau de la souris. Edition du Centre National de la Recherche Scientifique, Paris
39. Le Mevel JC, Olson KR, Conklin D, Waugh D, Smith DD, Vaudry H, Conlon JM (1996) Cardiovascular actions of trout urotensin II in the conscious trout, Oncorhynchus mykiss. Am J Physiol 271:1335-1343
40. Lin Y, Tsuchihashi T, Matsumura K, Abe I, Lida M (2003) Central cardiovascular action of urotensin II in conscious rats. J Hypertens 21:159-165
41. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180-185
42. Liu QY, Pong SS, Zeng ZZ, Zhang Q, Howard AD, Williams DL, Dividoff M, Wang RP, Austin CP, McDonald TP, Bai C, George SR, Evans JF, Caskey CT (1999) Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 266:174-178
43. Lu Y, Zou CJ, Huang DW, Tang CS (2002) Cardiovascular effects of urotensin II in different brain areas. Peptides 23:1631-1635
44. Maguire JJ, Kuc RE, Davenport AP (2000) Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 131:441-446
45. Marchese A, Heiber M, Nguyen T, Heng HH, Saldivia VR, Cheng R, Murphy PM, Tsui LC, Shi X, Gregor P, George SR, O'Dowd BF, Docherty JM (1995) Cloning and chromosomal mapping of three novel genes, GPR9, GPR10 and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics 29:335-344
46. Matsumoto Y, Abe M, Watanabe T, Adachi Y, Yano T, Takahashi H, Sugo T, Mori M, Kitada C, Kurokawa T, Fujino M (2004) Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents. Neurosci Lett 358:99-102
47. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirita Y (2001) Co-expression of urotensin-II and its receptor (GPR14) in human cardiovascular and renal tissue. J Hypertens 19:2185-2190
48. Mori M, Sugo T, Abe M, Shimomura Y, Kurihara M, Kitada C, Kikuchi K, Shintani Y, Kurokawa T, Onda H, Nishimura O, Fujino M (1999) Urotensin II is the endogenous ligand of G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Commun 265:123-129
49. Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, Duckles SP, Civelli O (1999) Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1:383-385
50. Owens MJ, Nemeroff CB (1991) Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 43:425-473
51. Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS, Bern HA (1980) Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci U S A 77:5021-5024
52. Pelletier G, Lihrmann I, Vaudry H (2002) Role of androgens in the regulation of urotensin II precursor mRNA expression in the rat brainstem and spinal cord. Neuroscience 115:525-532
53. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-167
54. Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327-336
55. Rampin O, Jérôme N, Suaudeau C (2003) Proerectile effects of apomorphine in mice. Life Sci 72:2329-2336
56. Rodgers RJ, Haller J, Holmes A, Halasz J, Walton TJ, Brain PF (1999) Corticosterone response to the plus-maze: high correlation with risk assessment in rats and mice. Physiol Behav 68:47-53
57. Rodriguez Echandia EL, Broitman ST, Foscolo MR (1987) Effects of the chronic ingestion of chlomipramine and desipramine on the hole board response to acute stresses in male rats. Pharmacol Biochem Behav 26:207-210
58. Schwartz MW, Woods SC, Porte D Jr, Seely RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404:661-671
59. Semba J, Takahashi R (1988) Effect of monoamine precursors on the forced-swimming test in mice. Psychopharmacology 95: 222-225
60. Sheline YI (2000) 3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity. Biol Psychiatry 48:791-800
61. Simon P, Charpentier S, Costentin J (1991) An automated method for the assessment of spontaneous and stereotyped climbing behavior in mice. Effects of the selective D1 and D2 dopamine receptor agonists SKF 38393 and RU 24926 and their association. Methods Find Exp Clin Pharmacol 13:99-104
62. Soubrié P, Chermat R, Poncelet M, Simon P (1978) Models of inhibition in animal behavior. Encéphale 4:503-511
63. Steru L, Chermat R, Thierry B, Mico JA, Lenegre A, Steru M, Simon P, Porsolt RD (1987) The automated suspension test: a computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatry 11:659-671
64. Sugo T, Murakani Y, Shimomura Y, Harade M, Abe M, Ishibashi Y, Kitada C, Miyajima N, Suzuki N, Mori M, Fujino M (2003) Identification of urotensin II-related peptide as the rat brain. Biochem Biophys Res Commun 310:860-868
65. Sunal R, Gümüsel B, Kayaalp SO (1994) Effect of changes in swimming area on results of behavioral despair test. Pharmacol Biochem Behav 49:891-896
66. Takeda H, Tsuji M, Matsumiya T (1998) Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. Eur J Pharmacol 350:21-29
67. Tal Ammar DA, Karpuj M, Krizhanovsky V, Naim M, Thompson DA (1995) A novel putative neuropeptide receptor expressed in neural tissue, including sensory epithelia. Biochem Biophys Res Commun 209:752-759
68. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Hironobu S, Murakami O (2001) Role of urotensin II in patients on dialysis. Lancet 358:810-811
69. Watson AMD, Lambert GW, Smith KJ, May CN (2003) Urotensin II acts centrally to increase epinephrine and ACTH release and causes potent ionotropic and chronotropic actions. Hypertension 42:373-379
70. Woods SC, Seely RJ (2000) Adiposity signals and the control of energy homeostasis. Nutrition 16:894-902